

CURRICULUM VITAE

RAYMOND DEAN HAUTAMAKI, M.D., FCCP

PRESENT POSITION:

Hautamaki & Horiuchi LLC
Personal Physicians of Sarasota
1843 Floyd Street
Sarasota, FL 34239
Telephone: 941-951-3920
Fax: 941-952-3922
(e-mail: Drs@H2MD.com or www.H2MD.com)

RESEARCH ADDRESS:

C/O Clinical Research Center
1540 S. Tamiami Trail 3rd Floor
Sarasota, FL 34239
Phone: 941-917-2225

EDUCATION:

University of Florida, College of Liberal Arts and Science,
Gainesville, FL., B.S., 1982-1986.

University of Florida, College of Medicine, Gainesville, FL.,
M.D., 1985-1989.

POSTGRADUATE:

University of Florida Health Science Center- Shands Hospital,
Gainesville, FL., General Surgery Internship, 7/1/89 – 6/30/90.

University of Florida Health Science Center- Shands Hospital,
Gainesville, FL., General Surgery Residency, 7/1/90 – 2/01/92.

Washington University School of Medicine, Barnes-Jewish
Hospital, 216 S. Kings Highway, St. Louis MO., 63110, Internal
Medicine Residency 6/24/92 – 6/29/94.

Washington University School of Medicine, Barnes-Jewish
Hospital, Department of Medicine, Respiratory and Critical Care
Division, 660 S. Euclid, St. Louis, MO., 63110, Fellowship
6/30/94 – 6/30/97.

BOARD CERTIFICATION:

Internal Medicine Board Certification - 1995 (ABIM # 159275)
Recertified 2005
Pulmonary Medicine Board Certification – 1996 (ABIM # 159275)
Recertified 2006
Critical Care Medicine Board Certification – 1997 (ABIM # 159275)

EMPLOYMENT:

Hautamaki & Horiuchi LLC - Partner
Personal Physicians of Sarasota
2130 South Tamiami Trail
Sarasota, FL 34239
09/15/08 - present

Private Physicians Services – Partner
1801 Arlington Street
Sarasota, FL 34239
01/01/05 – 09/07/08

Partner at Lung Associates of Sarasota
Multi-partner pulmonary, critical care and sleep medicine practice
1997 - 2004.

Staff Physician in Ambulatory Medicine, Bay Pines Veterans
Administration Medical Center, Bay Pines, FL
3/92 – 6/92.

Physician for the St. Louis Symphony Orchestra European Tour
10/31/93 – 11/14/93.

Washington University School of Medicine, Emergency Department
Attending, Barnes – Jewish Hospital
1994 – 1997 part-time.

LICENSURE: Florida License # ME 0059585

**DIRECTORSHIPS/ADVISORY
COMMITTEES:**

Wafergen Biosystems-Fremont CA, Board of Directors
2007 – Present

Medgenics - Misgav 20179 Israel, Scientific Advisory Board
2010 – 2014

First Wave Technology – Batavia NY, Board of Directors
2011 – Present

MEDICAL DIRECTORSHIPS/COMMITTEES:

Chairman of Medicine – Sarasota Memorial Hospital
Nov. 2014 – Oct. 2015

Medical Executive Committee - Sarasota Memorial Hospital
2013 - Present

Chairman of Medicine – Sarasota Memorial Hospital
2005-2006

HONORS/AWARDS:

C.R.C Freshman Chemistry Award, 1983
Golden Key National Honor Society,
Junior Honors Roll, 1984
Presidents Honor Roll, 1983-1985
Graduation with High Honors (B.S.), 1986 Phi Beta Kappa, 1986
N.I.H. Medical Student Research Scholarship, 1985-1986
Junior Honors Medical Program at University of Florida, 1985-1989

HONORS/AWARDS (Con't):

Honors Surgical Medical Student, 1987
Alpha Omega Alpha (Junior), 1988
Graduation with Honors (M.D.), 1989
Graduation with Honors in Research (M.D.), 1989
The James M. Murdock Award in Medical Therapeutics, 1989
The Edward R. Woodward Award in General Surgery, 1989
The John Gorrie Award (College of Medicine), 1989 (Outstanding Graduate)
American College of Surgery Research Scholarship, 1991
American Cancer Society Research Fellowship, 1991
Internal Medicine Book Award for Outstanding Resident, 1994
ACCP Fellow Representative (Washington University), 1995

PROFESSIONAL SOCIETIES/ORGANIZATIONS:

University of Florida College of Medicine Curriculum Committee Student
Representative (1987-1989)
University of Florida College of Medicine Alumni Affairs Student Representative
(1988-1989)
American College of Chest Physicians (Fellow)
American Thoracic Society
Society for Critical Care Medicine
American College of Physicians

RESEARCH ACTIVITIES:

Early Diagnosis of **Pulmonary Nodules** Using A **Plasma Proteomic
Classifier**

PIPF-031 A Treatment Protocol to Allow Patients in the US with Idiopathic
Pulmonary Fibrosis Access to Pirfenidone

A double blind randomized placebo controlled trial evaluating the effect of oral nintedanib 150 mg twice daily on high resolution computerized tomography quantitative lung fibrosis score, lung function, six minute walk test distance and St. George's Respiratory Questionnaire after twelve months of treatment in patients with Idiopathic Pulmonary Fibrosis with continued evaluations over a period of up to eighteen months

Metalloprotease contribution in smoking induced emphysema; Utilizing a transgenic murine model deficient in macrophage metalloelastase (MME).

IPS (idiopathic pneumonia syndrome) in bone marrow transplant recipients; Developing a murine model and defining MME's role in the development of this inflammatory lung condition. Supervised under Steven Shapiro, M.D., the department of pulmonary and Critical Care Medicine, Washington University School of Medicine (1996-1997).

Regulation of interorgan glutamine metabolism during critical illness and malignancy. Characterization of amino acid transport in type II alveolar cells. Supervised under W.W. Souba, M.D., Sc.D., Department of Biochemistry and Molecular Biology, and the Department of Surgery, University of Florida College of Medicine (1989-1992).

Neuropharmacology Research
Supervised under Edwin M. Myer, Ph.D Department of Pharmacology and Therapeutics University of Florida College of Medicine (1985-1987).

Red Tide (G. Brevis) Effects on pulmonary function in humans.
Mote Marine Research Institute, Sarasota, FL (1998-2000).

PUBLICATIONS:

1. Hautamaki, RD and Meyer, EM (1987) Effects of slow cooling in situ and freeze-thaw procedures hemicholinium-3 binding in rat cerebral cortical plasma membranes. *Biochem Pharmacol.* 36(4) : 561-562
2. O'Malley, E. and Hautamaki, RD, et al (1987) Effects of ovariectomy and estradiol benzoate on high affinity choline uptake, acetylcholine synthesis and release from rat cerebral cortical synaptosomes. *Brain Research* 403 (2) : 389-392
3. Klimberg, VS, Souba, WW, Sitren, H, Plumley, DA, Salloum, RM, Hautamaki, RD, Bland, KI, and Copeland, EM III (1990) Glutamine-enriched total parenteral nutrition supports gut metabolism. *Surge Forum* 40 : 175-177
4. Souba, WW, Klimberg, VS, Hautamaki, RD et al (1990) Oral glutamine reduces bacterial translocation following abdominal radiation. *J Surge Res* 48 : 1-5

5. Klimberg, VS, Souba, WW, Dolson, DJ, Salloum, RM, Hautamaki, RD, et al (1990) Prophylactic glutamine protects the intestinal mucosa from radiation injury. *Cancer* 66 (1) : 62-68
6. Klimberg, VS, Souba, WW, Salloum, RM, Holley, 8/27/98, Hautamaki, RD, et al (1990) Intestinal glutamine metabolism following massive small bowel resection. *AM J Surg* 159 : 27-33
7. Plumley, DA, Souba, WW, Hautamaki, ED et al (1990) Accelerated lung amino acid release in hyperdynamic septic surgical patients. *Arch Surg* 125 (1) : 57-61
8. Klimberg, VS, Souba, WW, Salloum, RM, Hautamaki, RD et al (1990) Oral glutamine accelerates healing of the small intestine and improves outcome following whole abdominal radiation. *Arch Surg* 125 : 1040-1045
9. Herskowitz, K, Plumley, DA, Martin, TD, Hautamaki, RD, Copeland, EM III, and Souba, WW (1991) Lung glutamine flux following open heart surgery. *J Surg Res* 51 : 82-86
10. Hautamaki, RD, Greene, B, and Souba, WW (1992) Characterization of L-glutamine transport by type II alveolar cells. *Am J Physiol* 262 : L459-L465
11. Hautamaki D, Bruya T, Kureishi A, et al. Short course (5-day) moxifloxacin versus 7-day levofloxacin therapy for treatment of acute exacerbations of chronic bronchitis. *Today's Ther Trends* 2001; 19: 117-36
12. Hautamaki, RD, Kobayashi, DK, Senior, RM, and Shapiro, SD, (1997) Requirement for Macrophage Elastase for Cigarette Smoke-Induced Emphysema in Mice. *Science* 277 : 2002-2004
13. Houghton, A, Grisolan, J, Baumann, M, Kobayashi, D, Hautamaki, RD, Nehring, L, Cornelius, L, and Shapiro, S, Macrophage Elastase Suppresses Growth of Lung Metastases. *Cancer Research* 66, 6149-6155. June 15, 2006

INVITED PUBLICATIONS/LECTURES/POSTER PRESENTATIONS:

High Affinity Choline Uptake in Rat Cerebral Cortical Plasma Membranes (1987) American Society of Neuroscience, Washington, DC.

Pernicious Anemia: A case report and review of the literature, (1993) Grand Rounds, Department of Medicine, Washington University School of Medicine, St. Louis, MO.

Nutritional Support in the Patient with Neoplastic Disease Editors Copeland, Bland and Karakousis, WB Saunders, Atlas of Surgical Oncology (1995) pp 741-748

Thoracic Trauma: Grand Rounds at Barnes Hospital, Washington University
School of Medicine, Department of Pulmonary and Critical Care Medicine,
1/18/96.

Poster Session, American Thoracic Society, May, 1996, New Orleans, LA.,
“Macrophage Metalloelastase Contribution in Cigarette Smoke Induced
Emphysema in Mice.”

INVITED PUBLICATIONS/LECTURES/POSTER PRESENTATIONS: (Cont'd)

Mini-Symposium, American Thoracic Society, May, 1997, San Francisco, CA.,
“Host defense against lung metastases is mediated by macrophage elastase.”

Poster Session, American Thoracic Society, May, 1997, San Francisco, CA.,
“Metalloprotease Contribution in the Idiopathic Pneumonia Syndrome in a Murine Bone Marrow Transplant Model.”

13th Annual Cardio-Pulmonary Seminar, July, 1998, Sarasota Memorial Hospital, Sarasota, FL., “Acute Respiratory Distress Syndrome.”

Mini-Symposium, American Thoracic Society, May, 2001, San Francisco, CA.,
“Murine macrophage elastase suppresses the growth of lung metastases.”

Mini-Symposium, American Thoracic Society, May, 2001, San Francisco, CA.,
“Five day Moxifloxacin compared to 7 day Levofloxacin therapy in the treatment of acute exacerbation of chronic bronchitis (AECB).”

APPOINTMENTS:

Medical Education Committee, Sarasota Memorial Hospital, Sarasota, FL. (1997-2008)

Special Care Committee, (ICU) Sarasota Memorial Hospital, Sarasota, FL. (1997-2008)

Thoracic Care Committee, Sarasota Memorial Hospital, Sarasota, FL. (1998-2008)

Infectious Disease Committee, Doctors Hospital of Sarasota, Sarasota, FL. (1997-2008)

Pulmonary Advisory Council, Doctors Hospital of Sarasota, Sarasota, FL. 1998-2004)

Board Member, American Lung Association, Gulf Coast Division. (1999-2001)

Medical Director, Critical Care, Sarasota Memorial Hospital, Sarasota, FL. (2002-2005)

Medical Executive Committee, Sarasota Memorial Hospital, Sarasota, FL. (2003-2005)

Interim Director, ICU, Sarasota Memorial Hospital, Sarasota, FL. (July 2003-Sept. 2004)

Associate Director, ICU, Sarasota Memorial Hospital, Sarasota, FL (July 2002-July 2003)

Chairman of Medicine, Sarasota Memorial Hospital, Sarasota FL (2005-2006)

TEACHING:

Clinical Associate Professor of Medicine, Florida State College of Medicine, Third year Internal Medicine Clerkship. (2005-present)

Co-Medical Director-Manatee Community College, Respiratory Therapy Division. (1998-2002)

Instructor, Manatee Community College-Respiratory Therapy Program. (1998-2002)

CLINICAL RESEARCH:

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital). Bayer Drug Study #98-Plum-45. Prospective, randomized, double-blind, multicenter comparison of the safety and efficacy of Moxifloxacin 400 mg QD for five days versus Azithromycin 250 mg QD (500 mg QD on the first day) for five days in the treatment of acute exacerbation of chronic bronchitis. Protocol #100160. (December 1997-February 1999)

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital). Bayer Drug Study #99-Plum-55. Prospective, randomized, double-blind, multicenter comparison of the safety and efficacy of Moxifloxacin 400 mg QD for five days versus levofloxacin 500 mg QD for seven days in the treatment of acute exacerbation of chronic bronchitis. Protocol #100243. (October 1999-May 2000)

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital). Bayer Drug Study #99-Pulm-55. Prospective, randomized, double-blind, study comparing Faropenem Daloxate 300mg PO BID for 5 days with Azithromycin for 5 days (500mg PO day 1, then 250mg PROD days 2-5) in the treatment of patients with acute exacerbation of chronic bronchitis. Bayer Protocol #100291 #00-PULM-39.

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital) A Randomized, Open-Label, Pilot Assessment Of The Effect Of Protonix Iv For Injection (Pantoprazole Sodium) On Gastric Ph In ICU patients.

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital). Salmeterol vs. Montelukast for Asthmatics who Require more Therapy (SMART) Study. A randomized, double-blind, multi-center study to evaluate the effect of adding either Montelukast Sodium or Salmeterol Xinofoate to Inhaled Fluticasone in Adult Asthmatics. Sponsor: Merck & Co. (February 2000-December 2000)

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital). Protocol Number: A0661035 "A Randomized, Multicenter, Open Label Trial Comparing Intravenous Zithromax (Azithromycin) With Intravenous Levaquin (Levofloxacin) Followed By Oral Levaquin

(Levofloxacin) For The Treatment Of Moderate To Severely Ill Hospitalized Subjects With Community-Acquired Pneumonia.

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital)

A one-year randomized, double-blind, placebo and active-controlled parallel design safety and efficacy comparison of COMBIVENT HFA Inhalation Aerosol to COMBIVENT (CFC) Inhalation Aerosol in patients with COPD

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital)

A 24-week, randomized, double-blind, placebo-controlled, parallel group study to Evaluate the Efficacy, Safety and Tolerability of Ariflo (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD) 00-PULM-51

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital). A

Multicenter, Randomized, Open-Label study comparing the Efficacy and Safety of Once Daily (O.D.) Org 31540/Sr90107a Versus Adjusted-Dose Intravenous (Iv) Unfractionated Heparin (Ufh) In the Initial Treatment of Acute Symptomatic Pulmonary Embolism (PE) 01-PULM-03

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital). A

Double-Blinded, Placebo-Controlled, Parallel Group Study of Uridine 5-Triphosphate (UTP) Solution for Inhalation as a Adjunct in the Diagnosis of Lung Cancer by Sputum Cytology (Inspire Lung CA) 01-PULM-12

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital)

A Double-blind, Efficacy, Safety Study of the Oral Direct Thrombin Inhibitor, H376/95 versus Standard Therapy (Enoxaparin and Warfarin (Coumadin) in Patients with Acute, Symptomatic Deep Venous Thrombosis with or without Pulmonary Embolism (THRIVE V) 00-MEDI-24

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital). A

Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Evaluation of the Safety and Efficacy of a-hANP Infusion (Carperitide for Injection: Sun 4936) in Patients with Acute Respiratory Distress Syndrome (ARDS) Protocol No. SPI-001 #99-PULM-47.

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital)

Title: A randomized, double-blind, placebo-controlled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD). Sponsor: Boehringer Ingelheim Pharmaceuticals, Inc. 02-PULM-21

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital)

A multicentre, randomized, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of

salmeterol/fluticasone propionate (Seretide/Viani/Advair) 50/500ug bd, salmeterol 50ug bd and fluticasone propionate 500 ug bd, all delivered via the Diskus/Accuhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD_ over 3 years of treatment. 02-PULM-20

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital)
BY217/M2-111 Effect of roflumilast on exacerbation rate in patients with chronic obstructive pulmonary disease (COPD). A 52 week, multicenter, double-blind study with 500 mcg roflumilast once daily versus placebo. Atlanta

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital)
A four week, double-blind, placebo-controlled exploratory evaluation of FEV1.0 changes and safety of ono-6126 in patients with chronic obstructive pulmonary disease (COPD)

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital)
MI-CP079 “Phase II, Randomized, Double-blind, Multicenter Trial of Subcutaneous Amifostine (Ethyol) versus Placebo in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in patients with Unresectable Non-Small Cell Lung Cancer.

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital)
SCO40041: A Randomized, Double-blind, Parallel-Group Clinical trial evaluating the effects of the Fluticasone Propionate/Salmeterol combination product 250/50mcg BID via Diskus versus Salmeterol 50mcg BID via Diskus on Bone Mineral Density in subjects with Chronic Obstructive Pulmonary Disease (COPD).

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital) A
Randomized, Controlled, Double-blind, placebo-controlled, Phase 3 study of Safety and Efficacy of Pirfenidone in patients with Idiopathic Pulmonary Fibrosis (PIPF-006)

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital)
PIPF-002 An Open-label, Phase 2 study of the Safety and Efficacy of Oral Pirfenidone in patients with Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis.

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital)
PIPF-016 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital) A
Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution/Aztreonam 75 mg Powder and Solvent for Nebuliser Solution

in Subjects with non-CF Bronchiectasis and Gram-Negative Endobronchial Infection (AIR-BX2)

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER)

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital)BI 1199.187
A double blind randomized placebo controlled trial evaluating the effect of oral nintedanib 150 mg twice daily on high resolution computerized tomography quantitative lung fibrosis score, lung function, six minute walk test distance and St. George's Respiratory Questionnaire after twelve months of treatment in patients with Idiopathic Pulmonary Fibrosis with continued evaluations over a period of up to eighteen months

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital)
A Treatment Protocol to Allow Patients in the US with Idiopathic Pulmonary Fibrosis Access to Pirfenidone Protocol Number: PIPF-031

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital)
CTT116855: A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital)
BAY q 3939/15626: Randomized, double-blind, placebo-controlled, multicenter study comparing ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus placebo to evaluate the time to first pulmonary exacerbation and frequency of exacerbations in subjects with non-cystic fibrosis bronchiectasis

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital)
MA29895: An Exploratory Multicenter, Open-Label, Single Arm Study Of The Safety And Tolerability Of Pirfenidone(ESBRIET®) In Combination With Nintedanib (OFEV®) In Patients With Idiopathic Pulmonary